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Abstract 
Purpose: The aim of this study is to determine if dynamic optical imaging could provide 
comparable kinetic parameters to that of dynamic PET imaging by a near-infrared dye/
64Cu 
dual-labeled cyclic RGD peptide. 
Methods: The integrin αvβ3 binding RGD peptide was conjugated with a macrocyclic chelator 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic  acid  (DOTA)  for  copper  labeling  and 
PET imaging and a near-infrared dye ZW-1 for optical imaging. The in vitro biological activity of 
RGD-C(DOTA)-ZW-1 was characterized by cell staining and receptor binding assay. Six-
ty-min dynamic PET and optical imaging were acquired on a MDA-MB-435 tumor model. 
Singular value decomposition (SVD) method was applied to compute the dynamic optical 
signal from the two-dimensional optical projection images. Compartment models were used 
to quantitatively analyze and compare the dynamic optical and PET data.  
Results:  The  dual-labeled  probe 
64Cu-RGD-C(DOTA)-ZW-1  showed  integrin  specific 
binding in vitro and in vivo. The binding potential (Bp) derived from dynamic optical imaging 
(1.762 ± 0.020) is comparable to that from dynamic PET (1.752 ± 0.026).  
Conclusion:  The signal un-mixing process using SVD improved the accuracy of kinetic 
modeling of 2D dynamic optical data. Our results demonstrate that 2D dynamic optical im-
aging with SVD analysis could achieve comparable quantitative results as dynamic PET imaging 
in preclinical xenograft models. 
Key words: dual modality imaging, dynamic imaging, kinetic modeling, Singular value decompo-
sition (SVD), integrin αvβ3, RGD peptide. 
INTRODUCTION 
Molecular  imaging  technology  accelerates  the 
translation  of  preclinical  research  to  the  clinic  by 
providing physiological, anatomic and metabolic in-
formation through interrogating certain targets [1-3]. 
Among the imaging technologies, positron emission 
tomography  (PET)  has  been  well-established  as  a 
Ivyspring  
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clinical molecular imaging modality with high sensi-
tivity and deep tissue penetration [4, 5]. On the other 
hand,  optical  imaging,  because  of  its  non-radiation 
property and the relatively low cost, is more suitable 
for  high-throughput  preclinical  drug  evaluations  in 
small  animals  [6].  Near-infrared  (NIR)  dyes  (700  to 
900 nm emission wavelength) are of particular interest 
due to their low tissue absorption and low autofluo-
rescence [7, 8]. There are also increasing efforts to ap-
ply  optical  imaging  in  clinical  imaging  guided  sur-
gery,  endoscopy  and  interventional  procedures  [9, 
10].  
Integrins  are  ideal  pharmacological  targets  not 
only  because  they  play  a  key  role  in  angiogenesis, 
leukocytes function and tumor development but also 
because they are easy to access as cell surface recep-
tors  interacting  with  extracellular  ligands  [11,  12]. 
Among  the  integrin  members,  the  αvβ3  integrin, 
which  binds  to  arginine-glycine-aspartic  acid 
(RGD)-containing components of the interstitial ma-
trix  such  as  vitronectin,  fibronectin  and  thrombos-
pondin, is expressed in a number of tumor types such 
as melanoma, late stage glioblastoma, ovarian, breast, 
and prostate cancer [12]. Preclinical studies and clini-
cal trials showed that RGD containing peptides and 
RGD  peptidomimetics  are  effective  in  inhibition  of 
angiogenesis [13, 14]. Some RGD analogs are under 
clinical trials for tumor imaging [15] or therapy [13]. 
Therefore,  visualization  of  integrin  will  be  of  great 
benefit for the drug development, early detection and 
cancer therapy response monitoring [16-18].  
Compared with static imaging, dynamic imag-
ing followed by kinetic analysis can be used to quan-
titatively  calculate  the  perfusion/clearance  rates. 
Furthermore, dynamic imaging facilitates the separa-
tion  of  specific  signal  from  non-specific  signal  and 
thus can be applied to accurately measure the binding 
potential (Bp) of an agent [19]. In addition, parametric 
mapping of dynamic imaging emphasizes the spatial 
distribution of the specific signal at the voxel level, 
and  allows  interpretation  of  physiological  function, 
pharmacokinetics, as well as the behavior of a target 
molecule [20-23]. Dynamic imaging can be applied to 
both optical and PET data; however, the comparison 
of PET/optical dynamic imaging is rarely reported. 
Whether the 2D optical data could mimic 3D PET data 
and  derive  similar  dynamic  parameters  is  yet  un-
known.  
The  quantification  of  optical  imaging  is  very 
challenging because of photon scattering and tissue 
attenuation [6]. With Cy5.5 conjugated RGD peptide, 
Gurfinkel  et al.  [24]  performed  dynamic  optical  im-
aging and successfully calculated PK parameters us-
ing a three-compartment modeling. In this study, we 
designed, synthesized and characterized a 64Cu/ZW-1 
dual  labeled  imaging  agent, 
c(RGDyK)-C(DOTA)-ZW-1,  for  in  vivo  comparison 
and correlation of dynamic optical and PET imaging 
parameters.  Singular  value  decomposition  (SVD) 
model was applied to un-mix 3D optical signal from 
2D projection data, and kinetic modeling was used to 
separate  non-specific  components  from  specific 
binding component for both optical and PET dynamic 
data.  To  the  best  of  our  knowledge,  the  results 
demonstrated for the first time that dynamic optical 
imaging  could  provide  comparable  in  vivo  kinetic 
parameters to that of dynamic PET imaging.  
MATERIALS AND METHODS 
Synthesis of c(RGDyK)-Cys (DOTA)-ZW-1 
c(RGDyK)  was  reacted  with  Fmoc-Cys 
(Trt)-COOH  (5  eq.)  in  the  presence  of  2-(1H-7- 
azabenzotriazol-1-yl)--1,1,3,3-tetramethyl  uronium 
hexafluorophosphate methanaminium (HATU, 5 eq.) 
and 2% DIPEA in DMF using the conventional Fmoc 
chemistry. The reaction lasts for 2 h at room temper-
ature. Peptide was precipitated in cold ether and fur-
ther dried by vacuum. Before the HPLC purification, 
Fmoc group on Cysteine was removed by incubating 
with 20% piperidine for 30 min.  For  ZW-1 (ex/em; 
775/790  nm)  conjugation,  ZW-1-NHS  (1.5  eq.)  was 
reacted with c(RGDyK)-Cys in DMF with 2% DIPEA 
for 1 hour. After precipitation in cold ether, the pro-
tection group on Cysteine side chain was removed by 
treatment  with  TFA  cocktail  (TFA/H2O/TIS/EDT, 
85/5/5/5, v/v/v/v) to afford c(RGDyK)-Cys-ZW-1. 
The  compound  was  purified  by  reversed  phase 
HPLC. DOTA-maleimide (1.5 eq.) was reacted with 
c(RGDyK)-Cys-ZW-1 at pH 7.0 in PBS buffer for 1 h. 
The  c(RGDyK)-Cys(DOTA)-ZW-1  (RGD-C(DOTA)- 
ZW-1) was purified by HPLC under the condition of 
10%  to  55%  acetonitrile  containing  0.1%  TFA  in  30 
min.  HPLC-ES/MS  (m/z)  calculated/found: 
2173/2173. 
Radiolabeling 
RGD-C(DOTA)-ZW-1 was dissolved in DMSO to 
the final concentration of 10 µg/µl.  64Cu-CuCl2 was 
converted to 64Cu-Cu(OAc)2 by adding 0.98 mL of 0.4 
M NH4OAc (pH = 5.5) solution to 20 μL 64Cu-CuCl2. 
To  a  clean  Eppendorf  tube  was  added  80  µg  of 
RGD-C(DOTA)-ZW-1 solution and an aqueous solu-
tion of 64CuCl2 solution (~ 3 mCi). The reaction mix-
ture was then heated at 40C in a water bath for 20 
min. Thereafter, the radiochemical purity was deter-
mined using C-18 TLC plates (KC18F, 60 A, 200 μm, 
Whatman  USA),  developed  in  2%  ethylenedia-Theranostics 2012, 2(8) 
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minetetraacetic acid (EDTA) in water. The purity of 
the  radiolabeled  compound  was  further  analyzed 
using  an  HPLC  system.  UV  absorbance  was  moni-
tored at 214 nm, 778 nm  and radioactivity  was de-
tected  by  a  radiation  detector.  64Cu  labeled 
RGD-C(DOTA)-ZW-1 was purified via Sep-Pak C18 
Chromatography Cartridge (Waters, USA) by ethanol 
washing. The  final  product  was  then  formulated  in 
PBS, sterile filtered, and used for in vitro and in vivo 
experiments. 
Cell culture  
MDA-MB-435 cell line was purchased from the 
American Type Culture Collection (ATCC). The cells 
were grown in Leibovitz’s L-15 medium containing 
10%  (v/v)  fetal  bovine  serum  supplemented  with 
penicillin (100 µg/ml) and treptomycin (100 μg/ml) at 
37°C under 100% air atmosphere. 
Cell receptor binding assay  
Competition cell binding assay was done using 
integrin  αvβ3-specific  radioligand,  125I-echistatin. 
MDA-MB-435 cells were grown up to 80% confluency 
and then scraped off and resuspended with binding 
buffer  [25  mM  2-amino-2-(hydroxymethyl)-1,3- 
propanediol,  hydrochloride  (Tris–HCl),  pH  7.4,  150 
mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2 and 1 mM 
MnCl2, 0.1% bovine serum albumin (BSA)]. Incuba-
tion was conducted in a 96-well plate with each well 
containing  2×105  cells,  0.02  μCi  (0.74  kBq) 
125I-echistatin  (Perkin-Elmer),  0–20,000  nM  of 
RGD-C(DOTA)-ZW-1,  c(RGDyK)-ZW-1  and 
c(RGDyK) in 200 μL for 2 h on a shaker at room tem-
perature.  After  incubation,  cells  were  washed  three 
times with cold PBS containing 0.1% BSA. Thereafter, 
the  plate  was  heated  to  40°C  and  dried.  The  dried 
filter  membranes  were  punched  off  from  the  wells, 
collected  in  polystyrene  culture  test  tubes  (12×75 
mm), and counted for cell bound radioactivity (1480 
Wizard  3  gamma  counter;  Perkin-Elmer).  The  IC50 
values were calculated by nonlinear regression anal-
ysis  using  the  GraphPad  Prism  fitting  program 
(GraphPad Software, Inc., San Diego, CA, USA). Each 
data point is a result of the average of triplicate wells. 
Cell fluorescent staining 
For  cell  immunostaining,  MDA-MB-435  cells 
were seeded into eight-well chamber at the concen-
tration of 1×104 cells/well. The next day, cells were 
fixed by 90% cold ether for 20 min at -20°C. After be-
ing blocked by 10% BSA at 37°C, MDA-MB-435 cells 
were detected using 50 µg/ml integrin αvβ3 primary 
antibody (Abegrin) for 2 h at room temperature, and 
then visualized by FITC conjugated goat anti-human 
secondary antibody (1: 1000 dilution).  
Fixed cells were incubated with RGD-C(DOTA)- 
ZW-1 at room temperature for 1 h. To confirm that 
RGD-C(DOTA)-ZW-1  binds  specifically  to  integrin 
αvβ3, fixed MDA-MB-435 cells were blocked with 10% 
BSA  for  1  h  and  incubated  with  10  µM  unlabeled 
c(RGDyK)  before  RGD-C(DOTA)-ZW-1  (1  µM)  was 
added. After washing steps, cells were mounted with 
4′,  6-diamidino-2-phenylindole  (DAPI)-containing 
mounting medium and observed with an epifluores-
cence microscope (Olympus, X81). 
Animal studies 
All animal studies were conducted in accordance 
with  the  principles  and  procedures  outlined  in  the 
National Institutes of Health (NIH) Guide for the Care 
and Use of Animals, and under protocols approved 
by  the  NIH  Clinical  Center  Animal  Care  and  Use 
Committee  (CC/ACUC).  The  MDA-MB-435  tumor 
model which expresses medium level of integrin αvβ3 
was chosen for dynamic PET and optical imaging. The 
tumor model was established by injecting 5×106 cells 
into the left mammary fat pad of each female athymic 
nude mouse at 5–6 weeks of age (Harlan Laboratories, 
Frederick,  MD).  Tumor  growth  was  monitored  by 
caliper  measurements  three  times  a  week  after  the 
tumors are palpable. The mice were used for PET or 
optical  imaging  when  the  tumor  volume  reached 
about 300 mm3 (about 14 days after tumor inocula-
tion). The tumor volume was determined as the for-
mula: V=a × (b2)/2, where a and b are the length and 
width of each tumor in mm respectively.  
Acquisition of dynamic images 
Optical data acquisition and analysis were done 
using DyCE function in Maestro 2. 0 in vivo imaging 
system  (Cambridge  Research  &  Instrumentation, 
Woburn,  MA).  MDA-MB-435  tumor-bearing  mice 
were  each  injected  via  tail  vein  with  2  nmol  of 
c(RGDyK)-Cys(DOTA)-ZW-1 in 100 µl PBS. The mice 
were subjected to 1 h in vivo dynamic optical imaging 
by  Maestro  2.0  configured  for  NIR  detection.  The 
dynamic scanning started 20 s ahead of remote probe 
injection with a catheter. Typically, 10 s per frame was 
used for the first 900 s, 15 s/frame for the second 900 
s, and 25 s/frame for the last 1800 s. During the injec-
tion  and  image  acquisition  process,  the  mice  were 
anesthetized with 1.0-2.0 % isoflurane in oxygen de-
livered at a flow of 1.5 L/min. After completion of the 
image  acquisition,  spectral  un-mixing  yielded  the 
pseudocolored images of the pure spectrum of ZW-1. 
Image  pre-processing  and  analysis  were  performed 
using the DyCE software provided by the manufac-
turer. For quantitative comparison, regions of interest Theranostics 2012, 2(8) 
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(ROIs) were drawn over tumors and muscle, and the 
average signal (x106 photon/cm2/s) for each area was 
measured. Results were presented as mean ± std (n = 
5). 
Dynamic  PET  scans  were  performed  using  an 
Inveon PET  scanner (Siemens Preclinical Solutions). 
Each MDA-MB-435 tumor-bearing mouse was placed 
at the center of the field of view (FOV) of the scanner. 
The  dynamic  PET  data  acquisition  was  started  in-
stantaneously  before  the  injection  of  ~3.7  MBq 
64Cu-c(RGDyK)-Cys(DOTA)-ZW-1  in  100  µl  in  PBS 
via  tail-vein.  The  body  temperature  of  mice  was 
maintained  using  a  thermostat-controlled  thermal 
heater.  PET  Images  were  reconstructed  by 
2-dimensional ordered-subsets expectation maximum 
(OSEM) algorithm and the frame rates were 10×30s, 
20×60s, 5×120s and 5×300s. Results were presented as 
mean ± std (n = 5). 
Kinetic modeling and parameter estimation 
Kinetic analysis of regional time activity curves 
(TACs)  was  performed  with  both  two-tissue 
(three-compartment)  model  and  one-tissue 
(two-compartment)  model.  The  three-compartment 
model  describes  RGD  tracer  kinetics  in  the  tumor 
where each compartment represents the concentration 
of  the  unmetabolized  radiotracer  in  arterial  blood 
plasma (Cp), that of the free or non-specific binding 
tracer in interstitial and intracellular space (Ct) and 
that  of  the  tracers  specifically  bounded  to  integrin 
(Cm). The ROI (t) represents the sum of radioactivity 
from all compartments and a fraction of plasma con-
centration.  Similarly,  the  two-compartment  model 
describes RGD tracer kinetics using muscle as a ref-
erence tissue and ref(t)  represents free (non-specific 
binding) tracer in the reference tissue (muscle) region 
as a scheme shown in Figure A.  
 
 
 
 
 
Figure A. Scheme A. 
 
Based on Logan plot shown in Eq. 1, the ratio 
between the integral of Cp(t) and the instantaneous 
value of ROI(t), and the ratio between the integral and 
the  instantaneous  value  of  ROI(t)  become  linearly 
related when the exchange between the target tissue 
and plasma reaches an equilibrium (t > t*). 
    ….(1) 
Where DV denotes the distribution volume that 
can be easily calculated using linear regression. It is a 
measure of the capacity of the tissue to bind the par-
ticular tracer and can be regarded as the sum of spe-
cific (Vs = K1k3/(k2k4)) and nonspecific (VND = K1/k2) 
distribution. 
               ….(2) 
                  ….(3) 
Total volume of distribution is defined as: 
             ….(4) 
Where K1, k2, k3, and k4 are calculated by fitting the 
model to a 60-min dynamic PET data [25]. 
In this study, muscle is selected as the reference 
tissue  because  of  its  negligible  integrin  expression. 
The relationship between muscle uptake and plasma 
concentration  could  be  established  using  a 
two-compartment model as [26-28]: 
   ….(5) 
where ref(t) refers to uptake in reference tissue region 
and k2ref refers to the washout rate from  interstitial 
space into blood in reference tissue. Consequently, the 
integrated activity in the tumor normalized by tumor 
uptake versus that of the muscle becomes linear ac-
cording to 
   ….(6) 
The Logan graphical analysis is used to compute Bp. 
In Logan plot, the ratio of integrated tumor uptake Theranostics 2012, 2(8) 
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divided by tumor uptake is set as the y-axis, and the 
ratio  of  integrated  reference  tissue  uptake  divided 
tumor uptake is set as the x-axis. The slope of the lin-
ear portion of the Logan plot is calculated as distribu-
tion  volume  ratio  (DVR).  The  binding  potential  is 
computed as Bp = DVR-1. 
Note  that  binding  potential,  which  is  a  mac-
ro-parameter  reflecting  the  binding  affinity,  is  also 
defined as  
            …(7) 
Optical image compression – SVD analysis 
For  dynamic  optical  image  analysis,  singular 
value  decomposition  (SVD)  method  was  performed 
before kinetic modeling to un-mix the specific signal 
component of tumor from the 2D optical projection 
data [29]. First, the TACs of ROIs in tumor, muscle 
and  background  were  formed  as  2-dimention  spa-
tial-temporal matrices. After SVD performed on the 
data matrices, a series of eigenvalues and eigenvectors 
sorted  by  the  amplitude  of  energy  were  generated. 
We  then  applied  L-curve  method  to  threshold  the 
eigenvalues to identify the meaningful eigenvectors. 
The L-curve method is usually used to distinguish the 
signal  components  from  the  noise  components  in  a 
SVD result. This type of application was first intro-
duced by Lawson and Hanson [30] and then Miller 
[31]. By comparing the resulting eigenvectors in three 
ROIs,  the  specific  tumor  component  and  muscle 
component were consequently identified. Finally, the 
time course of tumor was recovered by projecting the 
original time course to specific tumor eigenvector. The 
same method was applied to the reference region and 
the  time  course  of  muscle  was  obtained.  The  sepa-
rated  time-intensity  curves  of  tumor  and  reference 
tissue  were  fed  to  the  Logan  graphical  analysis  to 
compute the kinetic parameters as described above. 
Statistical methods 
Quantitative data were expressed as mean ± SD. 
Means  were  compared  using  one-way  analysis  of 
variance and Student’s t test. P value of < 0.05 was 
considered statistically significant. 
RESULTS 
Peptide synthesis and characterization 
To  conjugate  both  the  macrocyclic  chelator 
DOTA and NIR dye ZW-1 on one compound to form 
a dual functional agent, we designed a RGD analogue 
containing one Cysteine at ε-amine group of the lysine 
residue. As shown in Figure 1A, this structure allows 
specific chemical modifications on either the mercapto 
group or the amine group. ZW-1 with NHS functional 
group was introduced onto the cysteine amine group 
of  c(RGDyK)-Cys  (red  colored),  while  DOTA  was 
conjugated  based  on  the  reaction  of  Cysteine  mer-
capto group with DOTA maleimide (green colored).  
The purity and molecular weight were verified 
by  HPLC  and  LC-MS.  The  resulting 
RGD-C(DOTA)-ZW-1  probe  demonstrated  long 
wavelength NIR fluorescence (excitation maximum = 
775 nm, emission maximum = 790 nm) as shown in 
Figure 1B, which is optimal for NIR optical imaging. 
For  PET  imaging,  64Cu  was  labeled  with  DOTA  as 
reported previously [32]. 
 
Figure 1 A. Chemical structure of dual-labeling cyclic RGD monomer analog, c(RGDyK)-C(DOTA)-ZW-1. B. Excitation and emission 
spectra of c(RGDyK)-C(DOTA)-ZW-1.  
 Theranostics 2012, 2(8) 
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Competitive cell binding assay 
The receptor binding affinity of c(RGDyK) and 
RGD-C(DOTA)-ZW-1 for integrin αvβ3 was measured 
and  compared  using  MDA-MB-435  cells,  which  are 
known to express medium level of integrin αvβ3 [33, 
34].  c(RGDyk)  showed  an  IC50  value  of  604.3  nM 
(Figure 2). After ZW-1 labeling and DOTA conjuga-
tion,  the  resulting  compound  RGD-C(DOTA)-ZW-1 
remained  similar  binding  affinity  for  integrin  αvβ3 
(IC50 = 924.5 nM).  
Cell staining 
As shown in Figure 3, positive integrin αvβ3 ex-
pression  on  MDA-MB-435  cells  was  confirmed  by 
strong fluorescent signal observed with a specific an-
tibody  Abegrin.  After  incubating 
RGD-C(DOTA)-ZW-1 with MDA-MB-435 cells, strong 
signals were observed under the NIR filter by fluo-
rescence microscopy (Olympus). The fluorescent sig-
nal  from  the  RGD-C(DOTA)-ZW-1  could  be  effec-
tively inhibited when the cells were pre-treated with 
free  c(RGDyK)  peptide,  indicating  the  specificity  of 
RGD-C(DOTA)-ZW-1 binding to integrin αvβ3. 
 
 
Figure 2 Competition of specific binding of  125I-echistatin with 
c(RGDyK) (red) and c(RGDyK)-C(DOTA)-ZW-1 (black) to αvβ3 
integrin positive MDA-MB-435 cells as determined by receptor 
binding assay (n = 3).  
 
 
 
Figure 3 In vitro fluorescence staining of integrin αvβ3 positive cells. Upper panel: integrin αvβ3 was detected using 50 µg/ml integrin αvβ3 
primary antibody (Abegrin) and visualized by FITC conjugated goat anti-human secondary antibody (1: 1000 dilution). Middle panel. 1 µM 
RGD-C(DOTA)-ZW-1 was used for cell labeling. Lower panel. 10 µM c(RGDyK) was used for blocking test. Green color is from FITC for 
integrin αvβ3, red color is from ZW-1 for RGD-C(DOTA)-ZW-1 and blue color is from DAPI for nuclei visualization (x400, Scale bar = 
10 µm).  Theranostics 2012, 2(8) 
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Dynamic PET and optical scans 
The  representative  coronal  section  images  at 
different  time  points  were  presented  in  Figure  4A. 
MDA-MB-435 tumors were clearly visible as early as 
10 min after tracer injection. Liver and kidneys were 
major  organs  for  tracer  clearance  and  consequently 
showed  relatively  high  radioactivity  accumulation. 
The time activity curves (TACs) of tumor and muscle 
were  presented  in  Figure  4B. 
64Cu-RGD-C(DOTA)-ZW-1  had  a  reasonable  tumor 
uptake (2.6 ± 0.2 %ID/g) around 5 minutes due to the 
first pass perfusion. At 1 hour post injection, a high 
tumor-to-background  contrast  (4.50  ±  0.18)  was  ob-
served. 
The representative 2D projected optical images 
at  different  time  points  were  shown  in  Figure  4C. 
Consistent with PET images, high signal intensity was 
observed in the kidney region. Tumors were distin-
guishable from surrounding background region with 
good contrast. There was not much liver signal ob-
served. TACs of tumor and muscle region of the op-
tical images showed similar pattern with PET images 
(Figure 4D).  
Optical image compression – SVD analysis 
SVD analysis of the time course of dynamic op-
tical image series was performed on  tumor, muscle 
and background ROIs, as shown in Figure 5A. The 
resulting eigenvalues of tumor and muscle ROIs were 
plotted  in  Figure  5B,  and  the  eigenvalues  of  back-
ground were illustrated in Figure 5C. The eigenvalues 
were plotted in log scale for better illustration. The 
first 4 eigenvectors of background, muscle and tumor 
ROIs sorted by the amplitude of energy were shown 
in Figure 5 D, E and F, respectively. The log scale ei-
genvalue curves obviously had L-shape and therefore 
a threshold was applied to each curve. After thresh-
olding there were three signal components in the tu-
mor ROI, two components in the muscle ROI and one 
component in the background ROI. The only signal 
component in the background was due to autofluo-
rescence, which appeared as the first component in 
the SVD results of all three ROIs because by nature it 
should be included in all the regions. The other signal 
component (second in the figure) of muscle ROI was 
corresponding  to  the  uptake  of  muscle,  which  was 
also the second component in the tumor ROI since the 
signal in the tumor ROI was a sum of the contribution 
of tumor and muscle in the overlapped region along 
the projection direction. In the tumor ROI, there were 
three signal components. The first two were from au-
tofluorescence and muscle, respectively, and the third 
one was the specific component of tumor. The original 
time course of tumor and muscle were then projected 
to  the  identified  components  to  recover  the  pure 
TACs of tumor and muscle.  
 
Figure 4 A. Representative coronal PET images of U87MG tumor-bearing mice derived from 1 h dynamic scan with injection of 2 nmol 
64Cu-RGD-C(DOTA)-ZW-1 (100 µCi, 3.7 MBq). B. Time activity curve generated from dynamic PET images. C. Representative 2-D 
projection images of U87MG tumor-bearing mice derived from 1 h dynamic optical scan after injection of 2 nmol RGD-C(DOTA)-ZW-1. 
D. Time activity curve generated from dynamic optical imaging. Arrows indicate tumor location. Theranostics 2012, 2(8) 
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The  recovered  tumor  and  muscle  time-activity 
curves  which  indicate  the  specific  binding  and  free 
compound in tumor region were obtained by using 
eigenvalue  projection  to  original  TAC  in  tumor  re-
gion, as shown in Figure 6A. To compare the sepa-
rated optical TACs with PET data, we also calculated 
the  specific  and  non-specific  components  in  tumor 
region by kinetic modeling. The specific and free PET 
TACs  shown  in  Figure  6B  showed  similar  pattern 
with optical data. 
Binding potential 
To calculate and compare the binding potential 
(Bp)  from  dynamic  PET  and  optical  data,  Logan 
graphical  analysis  were  applied  and  the  results  are 
shown in Figure  7. The Logan plots with reference 
tissue model derived from 60-min dynamic PET data 
showed  excellent  linearity  (Figure  7A).  The  Logan 
plots with reference tissue model derived from 60-min 
dynamic optical data with and without SVD analysis 
were shown in Figure 7B. Slopes of fitted lines repre-
sent DVRs and Bp = DVR-1. The Bp calculated from 
PET data was 1.752 ± 0.026. The Bp calculated from 
original dynamic optical data was 1.507 ± 0.113. With 
SVD  projected  data,  the  calculated  Bp  was  1.762  ± 
0.020, which was improved to be  more comparable 
with the PET result. 
 
Figure 5 A. Representative optical image indicating ROI locations where ROI-1 refers to tumor, ROI-2 represents muscle and ROI-3 is 
background. B. log scale eigenvalue curves of dominant singular values from SVD analysis in the tumor and muscle ROI sorted by energy, 
which illustrate the efficient vectors screened by threshold. C. log scale eigenvalue curves of dominant singular values from SVD analysis 
in background ROI sorted by energy, which illustrates the efficient vectors screened by threshold. D-F. Representative amplitudes of the 
dominant eigenvectors in the background (D), muscle (E), and tumor (F) ROI sorted by energy.  
 
Figure 6 A. PET imaging 
time-activity  curves  of 
specific  and  free 
(non-specific) components 
separated  from  total  tu-
mor  uptake  by  kinetic 
modeling.  B.  Projected 
time-activity  curves  re-
covered  by  SVD  analysis 
from  original  optical  dy-
namic images.  Theranostics 2012, 2(8) 
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Figure 7 A. Logan plots with reference tissue model derived from 60-min dynamic PET data, which showed excellent linearity of 
normalized  integrated  (Int)  tumor  activity  vs.  normalized  integrated  muscle  tissue  activity  effective  for  equilibrium  after  30  min 
post-injection. B. Representative Logan plots with reference tissue model derived from 60-min dynamic optical data with and without 
SVD analysis. Red line showed the linear fitting of original optical data and blue line showed the fitted line derived from time courses 
projected by dominant eigenvectors in SVD analysis. Slopes of fitted lines represent DVRs and Bp=DVR-1. The binding potential calculated 
from PET data is 1.752 ± 0.026. The Bp calculated from original dynamic optical data is 1.5074 ± 0.113 while that from SVD projected data 
is 1.7624 ± 0.02 which is improved to be comparable with the PET result. 
 
DISSCUSSION 
Due to the photon scattering and tissue attenua-
tion, accurate quantification of optical imaging is very 
challenging. The ability to localize and quantitatively 
reconstruct fluorescence parameters in biological tis-
sues is limited, although diffusion-based fluorescence 
enhanced tomography has been developed for both 
clinical applications and preclinical experiments [35, 
36]. Moreover, quantification based on static images is 
a simple add-up from tracers specifically bound to the 
receptors  and  those  from  blood  perfusion  and 
non-specific retention. Thus, to accurately assess the 
magnitude of  specific binding  of a tracer to the re-
ceptors, it is necessary to separate the overall signal 
into  perfusion  and  nonspecific  and  specific  binding 
components [25]. So far, several preclinical and clini-
cal  studies  confirmed  that  dynamic  imaging  and 
compartment  modeling  could  delineate  specific 
binding of imaging tracers to the receptors from other 
components, which allows for more accurate nonin-
vasive  quantification  of  receptor  expression  [25,  34, 
37]. 
In  order  to  perform  a  parallel  comparison  be-
tween PET and optical imaging, we conjugated both 
ZW-1 dye [38] and DOTA on the cyclic RGD peptide. 
The dual-labeled agent was found to maintain similar 
integrin αvβ3 binding affinity to that of c(RGDyK) in 
vitro, suggesting that dye (ZW-1) and chelating agent 
(DOTA) modification did not affect the biological ac-
tivity of RGD peptide. To make sure that the same 
amount of probe is administered for both optical and 
PET  imaging,  we  purposely  mixed  unlabeled 
RGD-C(DOTA)-ZW-1  into  the  radioactive  tracer  to 
make the injected dose of 2 nmol/mouse [39]. It has 
been  reported  that  the  tumor  uptake  of 
18F-Galacto-RGD  was  only  partially  blocked  by  6 
mg/kg of unlabeled RGD peptide, which was around 
200 nmol/mouse [40]. Thus the influence of unlabeled 
c(RGDyK)-C(DOTA)-ZW-1 should be minimal in this 
study. The same amount of injected probe also facili-
tated direct comparison of optical imaging with PET 
results. 
With a three compartment modeling, Gurfinkel 
et al. [24] successfully calculated pharmacokinetic pa-
rameters  of  Cy5.5-c(RGDfK)  in  a  subcutaneous  hu-
man Kaposi’s sarcoma tumor (KS1767) model. They 
concluded that the value of α + β may correlate to the 
molecularly specific cellular uptake of the conjugate, 
in which α + β represents the sum of all the rate con-
stants of the compartmental pharmacokinetic model. 
In  our  previous  study,  we  analyzed  and  compared 
pharmacokinetic  parameters  derived  from  dynamic 
PET imaging with monomeric, dimeric RGD peptides 
and  control  RAD  peptide  [41].  We  found  that  the 
binding  potential  (Bp=k3/k4)  is  more  related  to  the 
specific binding within the tumor. Thus, in this study, 
we adopted Bp as the major parameter for the data 
modeling.  
The optical images are 2-dimensional projection Theranostics 2012, 2(8) 
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of signals from the whole body while PET images are 
tomographic sections. Besides, photon scattering and 
tissue  attenuation  also  affect  the  accuracy  of  data 
quantification from optical imaging. It is thus of no 
surprise that the Bp value calculated from the original 
optical data set is significant lower than that from PET 
data  (1.507  ±  0.113  vs.  1.752  ±  0.026,  p  <  0.05).  To 
un-mix the specific signal component of tumor from 
the  2D  optical  projection  data,  we  applied  singular 
value  decomposition  (SVD)  method  before  kinetic 
modeling [29]. The signal components from the noise 
components  were  distinguished  by  L-curve  method 
[30, 31]. In fact, after SVD and “L” shape analysis, the 
TAC curve labeled as “tumor” is more related to the 
specific binding component from tumor region, while 
the curve labeled as “muscle” is more related to the 
non-specific perfusion component of the tracer (Fig-
ure 6). Consequently, the resulting TAC over tumor 
region on optical images showed similar pattern with 
that from PET images.  
CONCLUSION 
For the first time, dynamic optical imaging was 
quantitatively compared with dynamic PET imaging 
using a dual-labeled tracer. Dynamic optical imaging 
with SVD analysis could achieve comparable quanti-
tative results as dynamic PET imaging in preclinical 
xenograft models.  
SUPPLEMENTARY MATERIAL 
Fig.S1-S4. http://www.thno.org/v02p0746s1.pdf 
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